10P Phase I study of magrolimab (ONO-7913) and nivolumab (ONO-4538, NIV) in combination with FOLFOX and bevacizumab (Bev) or cetuximab (Cet) as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer (CRC)
K. Yamaguchi(Japanese Foundation For Cancer Research), T. Yoshino(National Cancer Center Hospital East), T. Denda(Chiba Cancer Center), Yu Sunakawa(St. Marianna University School of Medicine), Yuji Nishizawa(National Cancer Center Hospital East), Y. Komatsu(Hokkaido University Hospital), A. Takashima(National Cancer Center Hospital East), S. Boku(Kansai Medical University), Takashi Kudo(Osaka University), Hiroshi Yasui(Sapporo Medical University), Hiroki Hara(Saitama Cancer Center), Masamichi Yano(Osaka Rosai Hospital), Takashi Kato(Showa University), Mitsuru Yokota(Kurashiki Central Hospital), Takashi Yamaguchi(Nagasaki Ajisai Hospital), Aki Kawazoe(National Cancer Center Hospital East), Yoshiki Horita(Saitama International Medical Center), N. Machida(Kanagawa Prefectural Hospital Organization), Hiroshi Matsuoka(Nagoya University)
Cited by 2
Related Papers
Inhibitory effect of citrus nobiletin on phorbol ester-induced skin inflammation, oxidative stress, and tumor promotion in mice.
|PubMed|2000|334
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
|Annals of Oncology|2019|333
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
|Journal of Clinical Oncology|2022|306
A molecular chaperone inducer protects neurons from ER stress
|Cell Death and Differentiation|2007|249